Proactive Investors - Run By Investors For Investors

Canadian cannabis company Emerald Health Therapeutics files 17 US patent applications to protect product line

The patent applications advance the company's efforts to develop distinctive cannabis products for medical use as well as recreational purposes
patents
Cannabis is not legal at the federal level, but the US is considered an important “first to file” jurisdiction for intellectual property pertaining to cannabis

The cannabis company Emerald Health Therapeutics Inc (CVE:EMH, OTCQX:EMHTF) has filed 17 US patent applications to protect its array of Defined Dose cannabis dosage forms and formulations.

The new patent applications contribute to Emerald’s intellectual property portfolio and advance its efforts to develop distinctive cannabis products for medical use as well as recreational purposes.

Although cannabis is not legal at the federal level in the US, it is considered an important “first to file” jurisdiction for intellectual property pertaining to cannabis and cannabinoids. The Patent Cooperation Treaty permits Emerald to file Canadian and international versions of these US patent applications in 152 countries over the coming year.

The 17 patent applications relate to inhaled dosage forms for smoking as well as vaping and also cover capsule and edible cannabis.

READ: Emerald Health Therapeutics partners with cannabis researcher VivaCell to boost patent portfolio

Emerald Health is a licensed producer authorized by Health Canada to grow, sell and produce cannabis across the country.

A number of the Defined Dose cannabis products are already eligible for launch in Canada as the country is set to legalize recreational marijuana, starting tomorrow. But other products are set to be eligible following regulatory changes next year.

“We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety-enhanced through GMP-compliant production and enhance product utility achieved through knowledge of science,” said CEO Emerald Chris Wagner. “Emerald’s filing of these patent applications is an important step.”

Emerald also recently strengthened its intellectual property portfolio via a partnership with the cannabis-focused research facility VivaCell Biotechnologies. The institute will work with Emerald Health to evaluate formulas and determine consistent dosages as the company continues to develop medical and recreational cannabis products.

Emerald Health closed up 4.7% to hit $3.92 on Monday.

Contact Ellen Kelleher at [email protected]

View full EMH profile View Profile

Emerald Health Therapeutics Inc Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use